000661 长春高新
已收盘 02-13 15:00:00
资讯
新帖
简况
长春高新：屋尘螨变应原舌下片已获欧美批准
证券之星 · 02-13
长春高新：屋尘螨变应原舌下片已获欧美批准
长春高新：公司研发投入及产出是基于长期战略布局的系统性成果
证券之星 · 02-13
长春高新：公司研发投入及产出是基于长期战略布局的系统性成果
长春高新：GenSci122片、GS1-144、GenSci120注射液、GenSci128片等产品陆续获得美国临床批准
证券之星 · 02-13
长春高新：GenSci122片、GS1-144、GenSci120注射液、GenSci128片等产品陆续获得美国临床批准
长春高新业绩“雪崩”：生长激素神话终结后的转型阵痛
新浪证券 · 02-13
长春高新业绩“雪崩”：生长激素神话终结后的转型阵痛
长春高新(000661.SZ)：金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准
智通财经 · 02-09
长春高新(000661.SZ)：金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准
长春高新：公司相关销售费用系核心产品市场维护、新品商业化落地等经营发展的阶段性必要投入
证券之星 · 02-06
长春高新：公司相关销售费用系核心产品市场维护、新品商业化落地等经营发展的阶段性必要投入
长春高新：医药生物行业也是典型的科技 + 民生双属性行业
证券之星 · 02-06
长春高新：医药生物行业也是典型的科技 + 民生双属性行业
2月2日长春高新跌6.14%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 02-02
2月2日长春高新跌6.14%，招商国证生物医药指数(LOF)C基金重仓该股
长春高新(000661.SZ)：GS3-007a干混悬剂境内生产药品注册临床试验申请获受理
智通财经 · 02-02
长春高新(000661.SZ)：GS3-007a干混悬剂境内生产药品注册临床试验申请获受理
医保数据发布再升级；多家药企发布业绩预告
21世纪经济报道 · 02-02
医保数据发布再升级；多家药企发布业绩预告
长春高新：预计2025年全年每股收益盈利:0.37元至0.55元
证券之星 · 01-30
长春高新：预计2025年全年每股收益盈利:0.37元至0.55元
长春高新最新公告：2025年净利同比预降91%-94%
证券之星 · 01-30
长春高新最新公告：2025年净利同比预降91%-94%
股市必读：长春高新（000661）1月29日董秘有最新回复
证券之星 · 01-30
股市必读：长春高新（000661）1月29日董秘有最新回复
长春高新（000661）披露子公司伏欣奇拜单抗注射液临床试验申请获受理，1月28日股价下跌2.11%
证券之星 · 01-28
长春高新（000661）披露子公司伏欣奇拜单抗注射液临床试验申请获受理，1月28日股价下跌2.11%
长春高新最新公告：子公司金赛药业伏欣奇拜单抗注射液境内生产药品注册临床试验申请获得受理
证券之星 · 01-28
长春高新最新公告：子公司金赛药业伏欣奇拜单抗注射液境内生产药品注册临床试验申请获得受理
长春高新：聘请专家提升公司治理能力、市场竞争力和长期可持续发展能力
证券之星 · 01-27
长春高新：聘请专家提升公司治理能力、市场竞争力和长期可持续发展能力
长春高新(000661.SZ)：GenSci145片境内生产药品注册临床试验申请获批准
智通财经 · 01-23
长春高新(000661.SZ)：GenSci145片境内生产药品注册临床试验申请获批准
长春高新：AI技术提升药物研发效率
证券之星 · 01-15
长春高新：AI技术提升药物研发效率
长春高新最新公告：GenSci098注射液项目收到Yarrow一次性支付的7000万美元首笔付款
证券之星 · 01-15
长春高新最新公告：GenSci098注射液项目收到Yarrow一次性支付的7000万美元首笔付款
1月12日长春高新涨5.79%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 01-12
1月12日长春高新涨5.79%，招商国证生物医药指数(LOF)C基金重仓该股
加载更多
公司概况
公司名称：
长春高新技术产业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-18
主营业务：
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。
发行价格：
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":87.38,"timestamp":1770966180000,"preClose":87.6,"halted":0,"volume":3582210,"delay":0,"changeRate":-0.0025,"floatShares":400000000,"shares":408000000,"eps":2.351,"marketStatus":"已收盘","change":-0.22,"latestTime":"02-13 15:00:00","open":87.61,"high":88.27,"low":87.26,"amount":314000000,"amplitude":0.0115,"askPrice":87.38,"askSize":141,"bidPrice":87.37,"bidSize":41,"shortable":0,"etf":0,"ttmEps":2.351,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":5,"adr":0,"adjPreClose":87.6,"symbolType":"stock","openAndCloseTimeList":[[1770946200000,1770953400000],[1770958800000,1770966000000]],"highLimit":96.36,"lowLimit":78.84,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.55,"roa":"--","peRate":37.167163,"roe":"5.03%","epsLYR":6.42,"committee":0.546605,"marketValue":35646000000,"turnoverRate":0.009,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-02-24。","floatMarketCap":34918000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2611132191","title":"长春高新：屋尘螨变应原舌下片已获欧美批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611132191","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611132191?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:57","pubTimestamp":1770973027,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新02月13日在投资者关系平台上答复投资者关心的问题。其他疾病事项建议咨询专业的医护人员，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300026422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0057","000661","BK0239","BK0075","BK0028","BK0188"],"gpt_icon":0},{"id":"2611131719","title":"长春高新：公司研发投入及产出是基于长期战略布局的系统性成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2611131719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611131719?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:27","pubTimestamp":1770971228,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新02月13日在投资者关系平台上答复投资者关心的问题。请问贵公司的研发费用到底有多少真实投入到研发工作中？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300025354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0075","BK0028","BK0057","BK0188","000661"],"gpt_icon":0},{"id":"2611813172","title":"长春高新：GenSci122片、GS1-144、GenSci120注射液、GenSci128片等产品陆续获得美国临床批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611813172","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611813172?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:27","pubTimestamp":1770971227,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)02月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有几个项目在美国已经获批临床了的，目前分别进展到什么阶段了？长春高新回复：您好，近年来公司GenSci122片、GS1-144、GenSci120注射液、GenSci128片等产品陆续获得美国临床批准，相关产品会综合国内同产品研发进度及临床进展表现等，未来合理安排推进海外研发相关工作，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300025351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000661","BK0028","BK0046","BK0075","BK0188","BK0057"],"gpt_icon":0},{"id":"2611213567","title":"长春高新业绩“雪崩”：生长激素神话终结后的转型阵痛","url":"https://stock-news.laohu8.com/highlight/detail?id=2611213567","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611213567?lang=zh_cn&edition=full","pubTime":"2026-02-13 15:12","pubTimestamp":1770966720,"startTime":"0","endTime":"0","summary":"近日，“东北药茅”长春高新发布2025年度业绩预告，归母净利润预计仅为1.50亿元至2.20亿元，同比暴跌逾九成，创下近二十年最差表现。尤其令市场震惊的是第四季度单季亏损接近10亿元，同比增亏约360%至390%，呈现出罕见的业绩“断崖”。 曾经依赖生长激素这一“利润引擎”高歌猛进的长春高新，如今正面临产品降价、竞争加剧、新增长点尚未成型的多重压力。 长春高新业绩骤降的核心，直接指向其长期以来高度依赖的生长激素业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-02-13/doc-inhmscxf6010928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0075","BK0188","BK0239","BK0028","000661","BK0057"],"gpt_icon":0},{"id":"2610655243","title":"长春高新(000661.SZ)：金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2610655243","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610655243?lang=zh_cn&edition=full","pubTime":"2026-02-09 21:55","pubTimestamp":1770645339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新 发布公告，近日，公司子公司——长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准。注射用GenSci136是金赛药业自主研发的一款治疗用生物制品1类药物，拟用于治疗免疫球蛋白A肾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)：金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0028","BK0057","BK0075","BK0239","BK0188","BK0046"],"gpt_icon":0},{"id":"2609507475","title":"长春高新：公司相关销售费用系核心产品市场维护、新品商业化落地等经营发展的阶段性必要投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2609507475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609507475?lang=zh_cn&edition=full","pubTime":"2026-02-06 15:51","pubTimestamp":1770364267,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新02月06日在投资者关系平台上答复投资者关心的问题。投资者提问：销售费用50亿,公司净利润不到2亿。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600022709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0188","000661","BK0075","BK0057","BK0239"],"gpt_icon":0},{"id":"2609572625","title":"长春高新：医药生物行业也是典型的科技 + 民生双属性行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2609572625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609572625?lang=zh_cn&edition=full","pubTime":"2026-02-06 15:30","pubTimestamp":1770363030,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新02月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司董秘，现在国家大力提倡科技，我们医药生物类算不算科技公司，是不是半导体类的面子工程比医药类的民生福祉更重要，公司市值已经跌了80%且还在不断下跌，有什么办法能让市场重视一下我们医药公司？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600020490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0057","BK0188","BK0028","BK0046","163118","000808.SH","BK0239","000661"],"gpt_icon":0},{"id":"2608851131","title":"2月2日长春高新跌6.14%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608851131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608851131?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:47","pubTimestamp":1770022049,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日长春高新跌6.14%创60日新低，收盘报90.01元，换手率2.73%，成交量10.9万手，成交额9.9亿元。重仓长春高新的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共31家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为14.39亿元，最新净值0.4035，较上一交易日下跌0.98%，近一年上涨12.43%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0075","399441","161726","BK0057","000661","BK0046","BK0028"],"gpt_icon":0},{"id":"2608530851","title":"长春高新(000661.SZ)：GS3-007a干混悬剂境内生产药品注册临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608530851","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608530851?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:41","pubTimestamp":1770021699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司控股子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》，金赛药业GS3-007a干混悬剂的境内生产药品注册临床试验申请获得受理。公告显示，GS3-007a干混悬剂是金赛药业自主研发的口服小分子生长激素促分泌药物，注册分类为化药1类，拟用于特发性身材矮小(ISS)的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)：GS3-007a干混悬剂境内生产药品注册临床试验申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0075","BK0046","000661","BK0188","BK0239","BK0028","BK0057"],"gpt_icon":0},{"id":"2608887409","title":"医保数据发布再升级；多家药企发布业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887409","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887409?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:04","pubTimestamp":1769990666,"startTime":"0","endTime":"0","summary":"政策动向医保数据发布再升级2月1日，国家医保局官微发文称，医保数据工作组是医保部门的一项创新性工作。数据发布活动组织一年多以来，各地发布内容不断丰富，发布形式更加多样，一些地方基于按病种付费改革开展病种专题分析，为疾病诊疗资源消耗“画像”，为医疗机构提供更加具体、好用的管理工具。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638025174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638025174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0046","BK0077","LU2580892862.HKD","LU2580892789.USD","CDE","BK1161","BK0028","688331","LU1223083913.SGD","000661","LU1223082519.USD","LU2148510915.USD","LU1064130708.USD","300122","LU2488822045.USD","BK0196","BK0239","BK1574","LU1223082196.USD","BK0057","BK0188","09995","LU1969619763.USD","BK0075","688506","BK4017","LU1328615791.USD","LU1064131003.USD","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2607010377","title":"长春高新：预计2025年全年每股收益盈利:0.37元至0.55元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607010377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607010377?lang=zh_cn&edition=full","pubTime":"2026-01-30 20:07","pubTimestamp":1769774848,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新发布业绩预告，预计2025年全年每股收益盈利:0.37元至0.55元。根据相关会计政策要求及被授权方实际付款节点，授权合作相关款项在 2025 年度内尚未确认，因此未对报告期内业绩产生影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000041113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0075","000661","BK0028","BK0057","BK0239"],"gpt_icon":0},{"id":"2607019697","title":"长春高新最新公告：2025年净利同比预降91%-94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607019697","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607019697?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:20","pubTimestamp":1769768428,"startTime":"0","endTime":"0","summary":"长春高新公告称，公司预计2025年归属于上市公司股东的净利润为1.50亿元-2.20亿元，比上年同期下降91.48%-94.19%。报告期内，受行业竞争加剧等因素影响，公司控股子公司长春百克生物科技股份公司预计2025年度将出现亏损，导致公司相应业绩有所减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000034320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0057","BK0188","BK0028","BK0046","BK0239","000661"],"gpt_icon":0},{"id":"2607037578","title":"股市必读：长春高新（000661）1月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2607037578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607037578?lang=zh_cn&edition=full","pubTime":"2026-01-30 01:26","pubTimestamp":1769707572,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，长春高新报收于98.3元，上涨0.92%，换手率1.62%，成交量6.47万手，成交额6.29亿元。公司公告汇总关于子公司伏欣奇拜单抗注射液境内生产药品注册临床试验申请获得受理的公告长春高新控股子公司金赛药业申报的伏欣奇拜单抗注射液用于治疗非感染性葡萄膜炎的境内生产药品注册临床试验申请已获国家药品监督管理局受理。该药为全人源抗IL-1β单抗，拟用于非感染性葡萄膜炎，目前国内外尚无同类药物在该适应症领域获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000000848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0188","BK0028","BK0075","BK0057","BK0239"],"gpt_icon":0},{"id":"2606786712","title":"长春高新（000661）披露子公司伏欣奇拜单抗注射液临床试验申请获受理，1月28日股价下跌2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606786712","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606786712?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:09","pubTimestamp":1769609359,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，长春高新报收于97.4元，较前一交易日下跌2.11%，最新总市值为397.33亿元。近日，长春高新控股子公司金赛药业申报的伏欣奇拜单抗注射液用于治疗非感染性葡萄膜炎的境内生产药品注册临床试验申请已获国家药品监督管理局受理。伏欣奇拜单抗此前已获批开展子宫内膜异位症、结缔组织病相关间质性肺病、全身型幼年特发性关节炎等适应症的临床试验，并有适应症已提交上市申请或获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","BK0057","BK0046","000661","BK0075"],"gpt_icon":0},{"id":"2606790750","title":"长春高新最新公告：子公司金赛药业伏欣奇拜单抗注射液境内生产药品注册临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2606790750","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606790750?lang=zh_cn&edition=full","pubTime":"2026-01-28 19:10","pubTimestamp":1769598633,"startTime":"0","endTime":"0","summary":"长春高新公告称，公司控股子公司金赛药业收到国家药品监督管理局的《受理通知书》，金赛药业伏欣奇拜单抗注射液的境内生产药品注册临床试验申请获得受理。该药品拟用于治疗非感染性葡萄膜炎，目前国内外尚无同类药物在相同疾病领域获批上市。但医药产品具有高科技、高风险、高附加值的特点，药品的前期研发以及产品从研制、临床试验报批到投产的周期长、环节多，容易受到一些不确定性因素的影响，本次临床试验进程尚存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800036012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0057","000661","BK0239","BK0075","BK0028","BK0188"],"gpt_icon":0},{"id":"2606203764","title":"长春高新：聘请专家提升公司治理能力、市场竞争力和长期可持续发展能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2606203764","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606203764?lang=zh_cn&edition=full","pubTime":"2026-01-27 15:09","pubTimestamp":1769497753,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)01月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司高薪聘任的市值管理专家具体的工作职责是什么？长春高新回复：您好，公司前期所聘请的金融与专业领域的专家，主要目的是为了帮助公司在全面提升公司治理能力、市场竞争力和长期可持续发展能力等方面开展工作，但不是专门的市值管理专家，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700019851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","BK0239","BK0188","BK0075","BK0028","BK0046"],"gpt_icon":0},{"id":"2605742740","title":"长春高新(000661.SZ)：GenSci145片境内生产药品注册临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2605742740","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605742740?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:16","pubTimestamp":1769156168,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci145片的境内生产药品注册临床试验申请获得批准。GenSci145片是金赛药业开发的一款新型突变选择性PI3Kα抑制剂，属1类创新型化学药品，拟用于携带PIK3CA突变的局部晚期或转移性实体瘤的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)：GenSci145片境内生产药品注册临床试验申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0046","BK0239","BK0075","BK0028","BK0057","000661"],"gpt_icon":0},{"id":"2603077426","title":"长春高新：AI技术提升药物研发效率","url":"https://stock-news.laohu8.com/highlight/detail?id=2603077426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603077426?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:52","pubTimestamp":1768481567,"startTime":"0","endTime":"0","summary":"对于AI技术前期在公司层面应用效果等方面，例如在靶向递送RNA技术平台中，该平台利用AI算法赋能siRNA序列设计以及活性╱安全性评估，以提升预测准确性和降低脱靶风险；在裂解酶药物技术平台中，依托微生物资源及AI模型，提升特异性裂解酶的发现效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500038855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0057","BK0188","BK0028","BK0046","BK0239","000661"],"gpt_icon":0},{"id":"2603603144","title":"长春高新最新公告：GenSci098注射液项目收到Yarrow一次性支付的7000万美元首笔付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603144","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603603144?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:41","pubTimestamp":1768470068,"startTime":"0","endTime":"0","summary":"长春高新公告称，公司控股子公司金赛药业下属全资子公司赛增医疗已收到Yarrow Bioscience,Inc.一次性支付的7000万美元首笔付款，这是根据双方就GenSci098注射液项目订立的独家许可协议。GenSci098注射液是金赛药业自主研发的一种人源化促甲状腺激素受体拮抗型单克隆抗体，目前，GenSci098 注射液已于2024年8月同步在中国大陆及美国获批开展用于甲状腺相关眼病的临床试验，并于2025年10月在中国大陆获批开展用于弥漫性毒性甲状腺肿的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500029374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0239","BK0028","BK0057","BK0075","000661"],"gpt_icon":0},{"id":"2602948185","title":"1月12日长春高新涨5.79%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602948185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602948185?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:41","pubTimestamp":1768203693,"startTime":"0","endTime":"0","summary":"证券之星消息，1月12日长春高新涨5.79%，收盘报103.57元，换手率4.24%，成交量16.94万手，成交额17.25亿元。重仓长春高新的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共83家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4219，较上一交易日上涨1.54%，近一年上涨18.54%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200015175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161726","BK0188","399441","BK0239","BK0046","BK0057","BK0075","BK0028","000661"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771803293600,"stockEarnings":[{"period":"1week","weight":-0.032},{"period":"1month","weight":-0.141},{"period":"3month","weight":-0.1642},{"period":"6month","weight":-0.1444},{"period":"1year","weight":-0.0737},{"period":"ytd","weight":-0.0559}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"104055人(较上一季度减少4.63%)","perCapita":"3840股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}